Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review

doi:10.4254/wjh.v14.i3.525

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 3

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8518)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

342

WORD

109

HTML

3073

Figures (1-1)

577

Tables (1-4)

632

Sum=4733

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

373

Download

1177

Sum=1550

Publishing Process of This Article

Item

Count

Browse

562

Download

1695

Sum=2257

Mar 27, 2022 (publication date) through Mar 2, 2026

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Minireviews

World J Hepatol. Mar 27, 2022; 14(3): 525-534
Published online Mar 27, 2022. doi: 10.4254/wjh.v14.i3.525

Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review

Anna Maria Spera

Anna Maria Spera, Infectious Disease Unit, Universitary Hospital OO RR San Giovanni di Dio e Ruggi d'Aragona, Salerno 84131, Italy

Author contributions: Spera AM studied conception and design; data collection; analysis and interpretation of results; draft manuscript preparation; Spera AM finally reviewed the results and approved the final version of the manuscript.

Conflict-of-interest statement: The authors declare that they have no competing interests.

Corresponding author: Anna Maria Spera, MD, PhD, Doctor, Infectious Disease Unit, Universitary Hospital OO RR San Giovanni di Dio e Ruggi d'Aragona, Largo Ippocrate, Salerno 84131, Italy. annamariaspera@hotmail.it

Received: November 25, 2021
Peer-review started: November 25, 2021
First decision: December 27, 2021
Revised: January 11, 2022
Accepted: February 15, 2022
Article in press: February 15, 2022
Published online: March 27, 2022
Processing time: 118 Days and 19.8 Hours

Core Tip

Core Tip: Chronic hepatitis C virus (HCV) infection is a hard clinical challenge, especially regarding oncologic patients eligible to chemotherapy. HCV reactivation in this setting of population is due to iatrogenic immunosuppression and can impair cancer treatment and outcome. Several specialists still do not prescribe direct aging antivirals to oncologic patients affected by HCV infection, because no univocal guidelines on HCV treatment in oncologic setting are available. The review highlights the importance of screening HCV infection before starting oncologic treatment, the safety of direct aging antivirals treatment under chemotherapy and the utility of treating HCV infection in oncologic setting no compromising chemotherapy course and success.